Belongs to

• Solid Tumor Oncology Division

Types of Work

["2016"]

[[["Journal Articles",849],["Meeting Abstracts",652],["Book Sections",37],["Editorials",25],["Reviews",15],["Research Letters",8],["Guidelines",6],["Correspondences",3],["Books Whole",2],["Conference Papers",2],["Miscellaneous",2]]]

[1601]

Popular keywords

• adult
• article
• controlled study
• female
• human
• immunotherapy
• ipilimumab
• melanoma
• nonhuman
• priority journal

Recent Works

1. Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma

   Meeting Abstract

   Piperno-Neumann, S.; Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R. J.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; more...
   Journal of Translational Medicine (2022)

   Fulltext@MSK | Save
2. Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe vs. investigator's choice (IC) in first line metastatic uveal melanoma

   Meeting Abstract

   Hassel, J. C.; Rutkowski, P.; Baurain, J. F.; Butler, M. O.; Schlaak, M.; Sullivan, R. J.; Ochsenreither, S.; Dummer, R.; Kirkwood, J. M.; Joshua, A. M.; more...
   Journal of Translational Medicine (2022)

   Fulltext@MSK | Save
3. Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)

   Meeting Abstract

   Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; more...
   Journal of Clinical Oncology (2022)

   Fulltext@MSK | Save